Optical Newswire
1 - UnitedHealthcare’s Golden Rule Introduces Cost-Effective Dental and Vision Coverage Options for Consumers in Six States
INDIANAPOLIS-(Business Wire)-September 29, 2009 - UnitedHealthcare’s Golden Rule Insurance Company has introduced new cost-effective dental and vision care coverage options for individuals and families in Alaska, Arizona, Colorado, Iowa, South Dakota and Wyoming. The new dental plans are available...
2 - Computable Genomix Announces Contest For Genomics Researchers
MEMPHIS, Tenn.-(Business Wire)-September 29, 2009 - Memphis-based Computable Genomix today announced it will launch a contest on Oct. 1, 2009, to coincide with the release of GeneIndexer, the company’s next-generation Web-based text-mining tool. Publish or Perish will award a $10,000 grant to each...
3 - pSivida Reports Safety and Efficacy Results from 18-Month Interim Readout of Human PK Iluvien® Study
WATERTOWN, Mass.-(Business Wire)-September 29, 2009 - pSivida Corp (NASDAQ: PSDV)(ASX: PVA), a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today...
4 - Research and Markets: The Ophthalmic Pharmaceutical Market Outlook to 2014: Competitive Landscape, Pipeline Analysis, Growth Opportunities and Market Forecasts - Now Available
DUBLIN-(Business Wire)-September 25, 2009 - Research and Markets , dry eye syndrome, ophthalmic infections and inflammation, etc.? What are the most promising ophthalmic products in clinical development and their forecast commercial potential through 2014? Which companies are best positioned to...
5 - pSivida Corp. Reports Results for the Fourth Quarter and Fiscal Year Ended June 30, 2009
WATERTOWN, Mass.-(Business Wire)-September 24, 2009 - pSivida Corp. (NASDAQ: PSDV) (ASX: PVA) (FF: PV3), a drug delivery company with two of the only three ophthalmic sustained release delivery products approved by the FDA for treatment of back of the eye diseases, today announced financial...
6 - GE Centricity EMR Helps Power Community Health Network’s Latest Innovation
BARRINGTON, Ill.-(Business Wire)-September 24, 2009 - GE Healthcare, a leading provider of healthcare information technology, is providing digital medical record technology for the Jane Pauley Community Health Center (Indianapolis). The center, which opened Wednesday, is a unique collaboration...
7 - pSivida Anounces New Iluvien® Pilot Study in Patients with Macular Edema Secondary to Retinal Vein Occlusion
WATERTOWN, Mass.-(Business Wire)-September 23, 2009 - pSivida Corp. (NASDAQ:PSDV)(ASX:PVA)(FWB:PV3), a leading drug delivery company that has developed two of the only three products approved by the FDA for the long term, sustained release delivery of drug to treat chronic back of the eye disease...
8 - Lux Biosciences Reports Phase 1 Safety Results and Open Label Efficacy Results for LX214, a Potential Best-in-Class Treatment for Dry Eye
JERSEY CITY, N.J.-(Business Wire)-September 23, 2009 - Lux Biosciences, Inc. a privately held biotechnology company focused on the treatment of ophthalmic diseases, today announced results from a Phase 1 human safety and an open-label pilot efficacy study of the company’s potential best-in-class...
9 - Dr. Brian S. Boxer Wachler Introduces I-Brite™ Eye Whitening
BEVERLY HILLS, Calif.-(Business Wire)-September 22, 2009 - World renowned ophthalmologist and vision specialist Dr. Brian S. Boxer Wachler (“Dr. Brian”) introduces I-Brite™ eye whitening, an original and breakthrough procedure created to treat a very common problem: chronic red eyes. It is...
10 - PerkinElmer Launches Columbus™ 2.0 High Content Screening Platform for High-Volume Image Data Management and Analysis
BOSTON-(Business Wire)-September 21, 2009 - At the High Content Analysis East conference in Boston, PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, today announced the launch of the Columbus™ 2.0 platform, its flagship high content...
11 - Reportlinker Adds The Ophthalmic Pharmaceutical Market Outlook To 2014: Competitive Landscape, Pipeline Analysis, Growth Opportunities and Market Forecasts
NEW YORK-(Business Wire)-September 21, 2009 - Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds The Ophthalmic Pharmaceutical Market Outlook To 2014: Competitive landscape, pipeline analysis, growth opportunities and market forecasts...
12 - CIGNA Volunteer of the Year in Phoenix Gives Sight to the Needy
PHILADELPHIA-(Business Wire)-September 18, 2009 - The CIGNA (NYSE:CI) Foundation today named Dr. Eva Liang, an ophthalmologist with the Cigna Medical Group in Phoenix, as the company’s Volunteer of the Year. Dr. Liang founded the Sight for Life Foundation in 2001 while in private practice in Las...
13 - pSivida CEO to Discuss New Technologies in Retinal Drug Delivery at 5th Annual Ophthalmic Drug Development and Delivery Summit
BOSTON-(Business Wire)-September 18, 2009 - pSivida Corp, (NASDAQ:PSDV)(ASX:PSD)(FF:PSI), a leading drug delivery company, today announced that Dr. Paul Ashton, CEO, will lead a discussion on New Technologies in Retinal Drug Delivery at the 5th Annual Ophthalmic Drug Development and Delivery...
14 - pSivida Corp Announces Q4 and Fiscal Year 2009 Financial Results Release Date and Conference Call Information
WATERTOWN, Mass.-(Business Wire)-September 17, 2009 - pSivida Corp. (NASDAQ:PSDV), (ASX:PVA), (FF:PV3), a leading drug delivery company, today announced that its financial results for the fourth quarter and fiscal year ended June 30, 2009, will be released after market close on Thursday, September...
15 - Hythiam Raises Approximately $7 Million in Registered Direct Offering
LOS ANGELES-(Business Wire)-September 17, 2009 - Hythiam, Inc. (NASDAQ:HYTM) announced today that it has entered into definitive agreements to sell 9,333,334 shares of its common stock at a price per share of $.75 to institutional investors pursuant to a registered direct offering, representing...
16 - Research and Markets: The Comprehensive Ophthalmology Review Course is an Intensive Program Aimed at Residents, Fellows, and Practicing Ophthalmologists
DUBLIN-(Business Wire)-September 17, 2009 - Research and Markets , as well as payment of a processing fee. A note on the available formats: DVD: Includes 13 DVDs with carrying case, a comprehensive course syllabus on CD-ROM and activity posttest. CD: Includes 21 audio CDs, carrying case...
17 - EBD Group and Defined Health Form an Alliance on Conference Content
CARLSBAD, Calif. & ZURICH, Switzerland & FLORHAM PARK, N.J.-(Business Wire)-September 16, 2009 - EBD Group and Defined Health today announced the formation of an alliance that will help biopharmaceutical firms gain the insights they need to create and execute successful strategy. Under...
18 - Blind Patient Regains Sight with “Eyetooth” Implanted in Her Eye
MIAMI-(Business Wire)-September 16, 2009 - Blind for nine years, Sharron “Kay” Thornton has just regained her sight through a first-in-the-U.S. surgical procedure at Bascom Palmer Eye Institute at the University of Miami Miller School of Medicine. The procedure — modified...
19 - Los Angeles Cosmetic Surgeon Discusses Non-Surgical Facial Rejuvenation in Harper’s Bazaar Magazine
LOS ANGELES-(Business Wire)-September 16, 2009 - Dr. Kenneth D. Steinsapir, M.D., a Los Angeles cosmetic surgeon, is featured this September in Harper’s Bazaar, the iconic magazine which epitomizes all that is sophisticated in fashion and beauty, discussing a non-surgical alternative for those...
20 - Pilkington Acquires License from Research Frontiers to Produce and Offer Environmentally Friendly SPD-Smart Automotive Glass Products
FRANKFURT-(Business Wire)-September 15, 2009 - Today at the Frankfurt International Motor Show, Pilkington Group Limited announced that it has acquired a new license from Research Frontiers Inc. (Nasdaq: REFR) to offer SPD-Smart automotive end-products globally. Research Frontiers is the developer...
21 - OptiMedica Names Alan Marquardt as New Vice President, Regulatory, Clinical and Quality
SANTA CLARA, Calif.-(Business Wire)-September 15, 2009 - Global ophthalmic company OptiMedica Corp. has appointed Alan Marquardt to the newly created position of vice president, regulatory, clinical and quality. Marquardt joins OptiMedica with more than two decades of equivalent senior management...
22 - AzaSite® Production Increased in Response to Erythromycin Ophthalmic Ointment Shortage
ALAMEDA, Calif.-(Business Wire)-September 14, 2009 - InSite Vision Incorporated (OTCBB: INSV) today announced that Inspire Pharmaceuticals, its commercial partner for AzaSite® (azithromycin ophthalmic solution) 1% in the U.S and Canada, has committed to increasing production of AzaSite in...
23 - Alcon to Acquire Swiss Biotechnology Firm, ESBATech AG
HUENENBERG, Switzerland & ZURICH-(Business Wire)-September 13, 2009 - Alcon (NYSE:ACL) announced today that it has entered into a definitive agreement to acquire ESBATech AG, a Swiss biotechnology company. Alcon will pay ESBATech shareholders $150 million in cash at closing, plus contingent...
24 - Research and Markets: 2009 Worldwide Optical Goods Stores Industry Report
DUBLIN-(Business Wire)-September 11, 2009 - Research and Markets selling non-prescription eyeglasses. Related Industries Pharmacies & Drug Stores Department Stores Offices of Optometrists U.S. Census Categories NAICS 44613 - Optical Goods Stores is comparable to: SIC 5995 - Optical goods stores...
25 - Fitch Ratings Affirms McKesson's IDR at 'BBB+'; Outlook Stable
CHICAGO-(Business Wire)-September 10, 2009 - Fitch Ratings has affirmed the Issuer Default Rating (IDR) and debt ratings for McKesson Corp. (MCK) as follows. —IDR at 'BBB+'; —Senior unsecured credit facility at 'BBB+'; —Senior unsecured debt at 'BBB+'; —Short-term IDR at...
26 - Reportlinker Adds China Medical Equipment Market Analysis and Forecasts to 2015
NEW YORK-(Business Wire)-September 10, 2009 - Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds China Medical Equipment Market Analysis and Forecasts to 2015...
27 - Signature Eyewear Reports 15th Consecutive Profitable Quarter
LOS ANGELES-(Business Wire)-September 10, 2009 - Signature Eyewear, Inc. (OTCBB:SEYE) reported net income of $155,000 on net sales of $5.9 million for the quarter ended July 31, 2009 and net income of $570,000 on net sales of $18 million for the nine months ended July 31, 2009. This compares to...
28 - Presbia Introduces Breakthrough Micro-Lens Treatment for Presbyopia
AMSTERDAM-(Business Wire)-September 10, 2009 - Presbia Coöperatief U.A., an early-stage company focused on surgical solutions for presbyopia, today announced that it will unveil a breakthrough implantable micro-lens treatment for presbyopia at the European Society of Cataract and Refractive Surgery...
29 - Research and Markets: Eye Infections Therapy Area Pipeline Report Provides Insight Into the Pipeline Status of Eye Infections Drugs by Company and by Stage
DUBLIN-(Business Wire)-September 9, 2009 - Research and Markets has announced the addition of the "Eye Infections Therapy Area Pipeline Report" report to their offering. Life Science Analytics, Eye Infections Therapy Area Pipeline Report contains detailed information on the eye infections drug...
30 - Acucela Appoints Glen Y. Sato to Board of Directors
BOTHELL, Wash.-(Business Wire)-September 9, 2009 - Acucela, a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today the appointment of Glen Y. Sato, a partner in the Life Sciences and Corporate practice groups of the law firm Cooley...
31 - pSivida to Webcast Presentation at Rodman & Renshaw Health Care Conference
BOSTON-(Business Wire)-September 9, 2009 - pSivida Corp, (NASDAQ:PSDV)(ASX:PSD)(FF:PSI), a leading drug delivery company, today announced it will webcast a live presentation at the Rodman & Renshaw Annual Health Care Conference in New York, September 10. Dr. Paul Ashton, president and chief...
32 - Amerinet Named Provider of Choice by National Rural Health Association Partnership
ST. LOUIS-(Business Wire)-September 8, 2009 - In recognition of their commitment to helping rural healthcare providers reduce costs and improve quality, Amerinet, a leading national healthcare group purchasing organization, has been named a “Provider of Choice” by the National Rural Health...
33 - Lux Biosciences to Present at the Thomas Weisel Partners Health Care Conference
JERSEY CITY, N.J.-(Business Wire)-September 8, 2009 - Lux Biosciences, a privately held biotechnology company focused on the treatment of ophthalmic diseases, announced today that Ulrich Grau, Ph.D., the company’s president and chief executive officer, will present at the Thomas Weisel Partner’s...
34 - Hi-Tech Pharmacal to Release First Quarter Earnings and Hold Conference Call on September 9, 2009
AMITYVILLE, N.Y.-(Business Wire)-September 4, 2009 - Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) announced that the Company will release results for its first quarter of Fiscal Year 2010 ended July 31, 2009, prior to the market opening on Wednesday September 9, 2009 and will hold a conference call to...
35 - Christopher Payan to Depart Emerging Vision
GARDEN CITY, N.Y.-(Business Wire)-September 3, 2009 - Emerging Vision, Inc. (OTCBB – ISEE) today announced that Christopher Payan, the Company’s Chief Executive Officer and President, and the Company have determined not to renew Mr. Payan’s employment agreement which is set to expire on...
36 - Vivakor Announces Award of Grant from the National Institutes of Health-National Eye Institute
IRVINE, Calif.-(Business Wire)-September 3, 2009 - Vivakor, Inc. (OTCBB: VIVK) announced that the National Institutes of Health-National Eye Institute has awarded a grant to Vivakor, Inc. in Coralville, IA through the Small Business Innovation Research Awards. Vivakor will use the grant, which was...
37 - Merck Launches SAFLUTAN® (tafluprost) in International Markets
WHITEHOUSE STATION, N.J.-(Business Wire)-September 3, 2009 - Merck & Co., Inc. has launched SAFLUTAN® (tafluprost) in the United Kingdom and Spain, and additional launches in other countries are expected over the next several months, pending regulatory approvals, the Company said today...
38 - Dioptics Launches Haven Fits Over Sunwear™
SMITHFIELD, R.I.-(Business Wire)-September 2, 2009 - Dioptics Medical Products, Inc., a subsidiary of FGX International Inc., is launching Haven Fits Over Sunwear™ at the 2009 Vision Expo West show in Las Vegas, NV. This special collection features premium polarized sunglasses and ClipOns designed...
39 - Acucela to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
BOTHELL, Wash.-(Business Wire)-September 2, 2009 - Acucela, a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that Ryo Kubota, M.D., Ph.D., Acucela’s chairman, president and chief executive officer, will present a company...
40 - MedAssets to Present at Two Investor Conferences in September
ATLANTA-(Business Wire)-August 27, 2009 - MedAssets, Inc. (NASDAQ: MDAS) today announced that its management team will participate in investment firm conferences in September 2009. The Company is scheduled to present at Baird's 2009 Health Care Conference on Thursday, September 10 at 9:00 am ET in...
41 - Visiogen Announces Formation of European Subsidiary, Commencement of Controlled Commercial Release of Synchrony® Accommodating IOL
ROME-(Business Wire)-February 17, 2009 - Visiogen announced the formation of its European subsidiary and the commencement of the controlled commercial release of the Synchrony® accommodating intraocular lens in Europe at the winter meeting of the European Society of Cataract and Refractive Surgeons...
42 - Research and Markets: A Global Strategic Analysis on the Intraocular Lenses Markets in Millions of US$
DUBLIN, Ireland-(Business Wire)-February 17, 2009 - Research and Markets has announced the addition of the "Intraocular Lenses - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Intraocular Lenses in Millions of US$. The specific product...
43 - Lux Biosciences Initiates Phase 1 Study of LX214, a Development Candidate for Dry Eye Syndrome
JERSEY CITY, N.J.-(Business Wire)-February 17, 2009 - Lux Biosciences today announced that it has begun treating patients in a Phase 1 study with its third product candidate, LX214, a proprietary topical ophthalmic solution containing the next-generation calcineurin inhibitor voclosporin. The...
44 - Signature Eyewear Reports Net Income for 2008
LOS ANGELES-(Business Wire)-February 14, 2009 - Signature Eyewear, Inc. (OTCBB: SEYE) reported net income of $622,000 on net sales of $24.5 million for the fiscal year ended October 31, 2008. The Company has achieved four consecutive years of profitability. In fiscal 2007, Signature recorded net...
45 - Eye Disease Experts Present New Research on Vision
FORT WORTH, Texas-(Business Wire)-February 13, 2009 - The Alcon Research Institute (ARI) is holding its biennial symposium this weekend to review and discuss eye disease research completed by some of its newer, distinguished members. At this year’s symposium, ARI members will present and discuss...
46 - BIO-Europe Spring® 2009 Announces Program Highlights
CARLSBAD, Calif., ZURICH & MILAN-(Business Wire)-February 13, 2009 - EBD Group announced today that the third annual BIO-Europe Spring® partnering event, March 16–18, 2009 at the Milano Convention Centre (MIC), Milan, Italy, will host many of the biggest names in biotech. Featured on panels...
47 - Alcon Fourth Quarter Diluted EPS Increased 12.8 Percent
HÜNENBERG, Switzerland-(Business Wire)-February 12, 2009 - Alcon, Inc. (NYSE:ACL): 2008 Highlights Sales rose 12.4 percent to $6.29 billion Organic sales growth was 8.3 percent Achieved broad-based global market share gains Operating income margin improved by 1.6 percentage points Reported...
48 - Cystinosis Research Foundation Grants $425,528 to Researchers and Scientists in U.S., Europe for Rare Disease Studies
IRVINE, Calif.-(Business Wire)-February 12, 2009 - The Cystinosis Research Foundation announced it has awarded $425,528 in grants to researchers in the United States and Belgium who are working on new treatments and a cure for cystinosis, a rare, deadly metabolic disorder that afflicts about 500...
49 - Zeeko Technologies Expands Research of Optics-Polishing Technology
WEST LAFAYETTE, Ind.-(Business Wire)-February 11, 2009 - Zeeko Technologies LLC, a Purdue Research Park-based company, announced Wednesday (Feb. 4) that it will further develop its high-precision polishing technology for optics manufacturing through a Small Business Innovation Research grant. The...
50 - pSivida Corp. Reports Results for the Second Quarter Ended December 31, 2008; Iluvien™ NDA filing remains on schedule for early calendar 2010; Final two-year patient visit scheduled for October 2009
WATERTOWN, Mass.-(Business Wire)-February 11, 2009 - pSivida Corp. (NASDAQ: PSDV) (ASX: PVA) (FF: PV3), a drug delivery company, today announced financial results for the second quarter ended December 31, 2008. For the quarter ended December 31, 2008, the Company reported a consolidated net loss...
51 - OPKO To Present Data on Next Generation Anti-Angiogenic VEGF165b-Sparing siRNA at Association for Research and Vision in Ophthalmology (ARVO 2009) Meeting
MIAMI-(Business Wire)-February 10, 2009 - OPKO Health, Inc. (NYSE Alternext US:OPK) today announced that it will present initial data on the characterization of its next generation anti-VEGF siRNA molecules. These new proprietary siRNA’s are designed to inhibit the angiogenic Vascular...
52 - Advanced Medical Optics, Inc. Announces Increase in Total Consideration and Extension of Consent Deadline in Tender Offer and Consent Solicitation for Its 7½% Senior Subordinated Notes Due 2017
SANTA ANA, Calif.-(Business Wire)-February 10, 2009 - Advanced Medical Optics, Inc. (AMO) [NYSE:EYE], announced today that, in connection with its previously announced cash tender offer for its outstanding 7½% Senior Subordinated Notes due 2017 (the “Notes”) (CUSIP No. 00763MAN8, ISIN No...
53 - The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (NASDAQ: LCAV) and Send Letter to Stockholders
CINCINNATI-(Business Wire)-February 9, 2009 - The LCA-Vision Full Value Committee announced today that it has filed with the Securities and Exchange Commission definitive consent solicitation materials and is commencing distribution of those soliciting materials to stockholders of LCA-Vision, Inc...
54 - Research and Markets: Recently Updated In-Depth Comprehsive Company Intelligence Report for Carl Zeiss Medical Devices now Available
DUBLIN, Ireland-(Business Wire)-February 9, 2009 - Research and Markets Welch Allyn Acri.Tec Wavelight Laser Technologies Carl Zeiss Surgical Carl Zeiss SA Ioltech Laser Diagnostic Technologies Hiko medical communications Minority Investments Advanced Research Institute Elsia and PolymerExpert...
55 - Raquel Welch Stars in Foster Grant TV Commercial
SMITHFIELD, R.I.-(Business Wire)-February 9, 2009 - FGX International (NASDAQ: FGXI), a leading eyewear designer and marketer, announced today that it has released the latest television ad campaign for Foster Grant, featuring Hollywood legend Raquel Welch. The ads will begin airing on national...
56 - Biotechs Seek Partners at BIO-Europe Spring® as Alternative to Financial Markets
CARLSBAD, Calif. & ZURICH & MILAN-(Business Wire)-February 6, 2009 - The intensity of partnering activities among biotech executives continues to increase in the wake of the collapse of traditional sources for financing, according to EBD Group, producer of the annual BIO-Europe Spring...
57 - Advanced Medical Optics, Inc. Gives Notice of Anticipated Fundamental Change and Merger to Holders of Convertible Senior Subordinated Notes
SANTA ANA, Calif.-(Business Wire)-February 6, 2009 - Advanced Medical Optics, Inc. (AMO) (NYSE: EYE) announced that, pursuant to the terms of the indentures (the “Indentures”) governing its (i) 2.50% convertible senior subordinated notes due 2024, (ii) 1.375% convertible senior subordinated...
58 - Allergan Reports Fourth Quarter 2008 Operating Results and Announces Restructuring
IRVINE, Calif.-(Business Wire)-February 4, 2009 - Allergan, Inc. (NYSE: AGN) today announced operating results for the quarter ended December 31, 2008. Allergan also announced that its Board of Directors has declared a fourth quarter dividend of $0.05 per share, payable on March 13, 2009 to...
59 - ACADIA Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 10, 2009
SAN DIEGO-(Business Wire)-February 3, 2009 - ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the...
60 - Cataract Surgery and Macular Degeneration; Beauty in the Eye of the Beholder; Are Genes or Environmental Factors to Blame for Poorer Vision as We Age?
SAN FRANCISCO-(Business Wire)-February 2, 2009 - Does cataract surgery increase the risk of vision loss in people with age-related macular degeneration (AMD)? How do people read faces to judge age or fatigue? Which has a larger impact on the “normal” decline of visual function as we age, genetic...
61 - pSivida Corp. Names Paul Ashton, Ph.D. President and Chief Executive Officer
WATERTOWN, Mass.-(Business Wire)-February 2, 2009 - pSivida Corp. (NASDAQ:PSDV)(ASX:PVA)(FF:PSI), a leading drug delivery company today announced that Paul Ashton, Ph.D. has been named President and Chief Executive Officer. Dr. David J. Mazzo, Non-executive Chairman, pSivida Corp said, “The...
62 - ZOLL Announces Filing of Patent Infringement Suit Against Alsius Corporation and Alsius Medical Corporation
CHELMSFORD, Mass.-(Business Wire)-January 30, 2009 - ZOLL Medical Corporation (Nasdaq GS: ZOLL), a manufacturer of resuscitation devices and related software solutions, announced today that it had filed a lawsuit against Alsius Corporation (Nasdaq: ALUS) and Alsius Medical Corporation in the Central...
63 - Akorn Announces Management Change
LAKE FOREST, Ill.-(Business Wire)-January 30, 2009 - Akorn, Inc. (NASDAQ: AKRX) today announced that its President and Chief Executive Officer, Arthur Przybyl, is leaving the company and that, pending selection of a new President and Chief Executive Officer, a committee of three board members will...
64 - International Stem Cell Corporation Begins Pre-Clinical Trials on Human Corneal Epithelial Cells
OCEANSIDE, Calif.-(Business Wire)-January 29, 2009 - International Stem Cell Corporation (OTCBB:ISCO), the first company to perfect a method of creating human “parthenogenetic” stem cells from unfertilized eggs, is planning pre-clinical trials aimed at applying its laboratory-grown human corneal...
65 - Can-Fite Completed Patient Enrollment for the Phase II Trial in Dry Eye Syndrome with CF101
PETACH TIKVA, Israel-(Business Wire)-January 28, 2009 - Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange has achieved yet another goal by completion of enrollment of 80 patients in its phase II Dry Eye Syndrome trial. Approximately 80 patients were...
66 - Don’t Lose Sight of Your Eye Health
SAN FRANCISCO-(Business Wire)-January 28, 2009 - To many people, good vision means good eye health. But that is not necessarily true. A comprehensive eye examination can catch problems with your eyes well before your vision is affected. Aaron Weingeist, MD, an ophthalmologist in Seattle and a...
67 - CIGNA’s Behavioral Health Care Centers Earn Full Accreditation from The National Committee for Quality Assurance
BLOOMFIELD, Conn.-(Business Wire)-January 27, 2009 - In real estate it’s all about location. In health care it’s all about quality. At the end of 2008, all four of CIGNA's behavioral health care centers nationwide earned “Full” accreditation from the National Committee for Quality...
68 - Cubs Fans and Chicago Admirers Offered Movie Credit Spot in “We Believe – Chicago and its Cubs” Documentary Film
CHICAGO-(Business Wire)-January 27, 2009 - Chicago Cubs fans and admirers of the city of Chicago from around the world are being offered a once in a lifetime opportunity to include their name or the name of a loved one in the closing credits of the theatrical release or the DVD of the upcoming...
69 - Advanced Medical Optics, Inc. Announces Tender Offer and Consent Solicitation for Its 7½% Senior Subordinated Notes Due 2017
SANTA ANA, Calif.-(Business Wire)-January 27, 2009 - Advanced Medical Optics, Inc. (AMO) [NYSE:EYE], announced today that it has commenced a cash tender offer for its outstanding 7½% Senior Subordinated Notes due 2017 (the “Notes”) (CUSIP No. 00763MAN8, ISIN No. US00763MAN83) and a related...
70 - Inspire Initiates Phase 3 Prolacria™ Dry Eye Trial under Special Protocol Assessment Agreement
DURHAM, N.C.-(Business Wire)-January 27, 2009 - Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today it has reached agreement with the U.S. Food and Drug Administration (FDA) through a Special Protocol Assessment (SPA) on the design of a Phase 3 clinical trial for Prolacria™ (diquafosol...
71 - Alliance Medi-Cal Members to Receive Vision Care Services From March Vision Care
ALAMEDA, Calif.-(Business Wire)-January 26, 2009 - Alameda Alliance for Health is changing its vision care service provider from Vision Service Plan (VSP) to March Vision Care effective February 1, 2009. This change affects only Medi-Cal beneficiaries in Alameda County who currently receive their...
72 - IOPtima: Successful Results in Novel Glaucoma Treatment Using Laser-Based Therapy
RAMAT GAN, Israel-(Business Wire)-January 26, 2009 - IOPtima, the developer of an innovative laser based surgical device for reducing internal eye pressure for the treatment of glaucoma, successfully completed and analyzed the results of its first 6 month follow-up period of human clinical trials...
73 - New NIR Bandpass Filters SP for Distance Metering and Safety Applications
BALZERS, Liechtenstein-(Business Wire)-January 26, 2009 - Optics Balzers AG (SWX:OERL), the successor to Oerlikon Optics, has rolled out a new generation of NIR Bandpass Filters designed for very high blocking of visible light. The NIR Bandpass Filters SP are produced with advanced sputtering...
74 - Alcon Placed for the 11th Consecutive Year on FORTUNE Magazine’s List of ‘100 Best Companies to Work For’
HUENENBERG, Switzerland-(Business Wire)-January 23, 2009 - Alcon, Inc. (NYSE:ACL) announced today that for the 11th consecutive year, the company’s U.S. affiliate, Alcon Laboratories, Inc., was named to FORTUNE’s “100 Best Companies to Work For” list, placing 74th. “Here at Alcon, we all...
75 - Advanced Cell Provides Corporate Update
WORCESTER, Mass.-(Business Wire)-January 23, 2009 - Advanced Cell Technology, Inc. (“ACT”) (OTC: ACTC) provided a corporate update today. The Company announced that it has accelerated its efforts to file an IND for its retinal pigment epithelium (RPE) cells program for the treatment of...
76 - OPKO Receives FDA 510(k) Clearance for Spectral OCT SLO Combination Imaging System
MIAMI-(Business Wire)-January 23, 2009 - OPKO Health, Inc. (NYSE Alternext US:OPK) today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to begin marketing in the United States its Spectral OCT SLO Combination Imaging System. Currently...
77 - Orange 21 Inc. Announces $7.6 Million Rights Offering
CARLSBAD, Calif.-(Business Wire)-January 22, 2009 - Orange 21 Inc. (NASDAQ:ORNG) today announced that it has launched a $7.6 million rights offering pursuant to which holders of its common stock, options and warrants, will be entitled to purchase additional shares of its common stock at a price of...
78 - OPKO Health Initiates Clinical Trial of the Aquashunt™ to Treat Glaucoma
MIAMI-(Business Wire)-January 22, 2009 - OPKO Health, Inc. (AMEX:OPK) announced today that it has begun treating patients in a clinical trial of its Aquashunt™, a device for the treatment of refractory open angle glaucoma. The study, at two academic departments of ophthalmology, is designed to...
79 - Larry C. Renfro Named Executive Vice President UnitedHealth Group and Ovations Chief Executive Officer
MINNEAPOLIS-(Business Wire)-January 22, 2009 - UnitedHealth Group (NYSE: UNH) today named Larry C. Renfro executive vice president UnitedHealth Group and chief executive officer of Ovations. Ovations is UnitedHealth Group’s seniors health business and the nation’s largest and most diversified...
80 - Simon Stevens Appointed Executive Vice President UnitedHealth Group to Lead Enterprise-Wide Health Care Reform Engagement; Will Also Direct International Businesses and Global Expansion
MINNEAPOLIS-(Business Wire)-January 22, 2009 - UnitedHealth Group (NYSE: UNH) announced today that Simon Stevens will serve as executive vice president, UnitedHealth Group, with major responsibilities in the areas of health care reform and global health interests. In his new role, which reports to...
81 - Genentech Announces Vice President Appointment in Research
SOUTH SAN FRANCISCO, Calif.-(Business Wire)-January 21, 2009 - Genentech, Inc. (NYSE:DNA) today announced the appointment of Jennifer A. Doudna, Ph.D., to Vice President, Discovery Research. In this newly created position, Doudna will oversee the departments of protein chemistry and structural...
82 - Examine the Global Ophthalmic Market: Focus on Glaucoma
NEW YORK-(Business Wire)-January 21, 2009 - Reportlinker.com announces that a new market research report related to the Ophthalmic devices industry is available in its catalogue. Global Ophthalmic Market: Focus on Glaucoma...
83 - Welch Allyn Introduces Suite of Metal Halide Fiber-Optic Illuminators for Medical, Industrial Applications
SKANEATELES FALLS, N.Y.-(Business Wire)-January 20, 2009 - Welch Allyn Lighting Products, a premier manufacturer of high-performance lighting and technology, introduces the “LB24” suite of Sōlarc metal halide fiber-optic illuminators for medical and industrial applications. LB24 products are...
84 - Advanced Medical Optics Receives FDA Approval for TECNIS® Multifocal Intraocular Lens
SANTA ANA, Calif.-(Business Wire)-January 16, 2009 - Advanced Medical Optics, Inc. (AMO) (NYSE:EYE), the global leader in advanced refractive technologies for eye care professionals and patients, today announced U.S. Food and Drug Administration (FDA) approval of the TECNIS® Multifocal...
85 - The LCA-Vision Full Value Committee Files Preliminary Consent Solicitation Statement to Reconstitute the Board of Directors of LCA-Vision Inc.
CINCINNATI-(Business Wire)-January 16, 2009 - The LCA-Vision Full Value Committee (the “Committee”) today reported that it has filed with the Securities and Exchange Commission a preliminary consent statement to undertake a consent solicitation to reconstitute the board of directors of...
86 - Genentech Announces Full Year and Fourth Quarter 2008 Results
SOUTH SAN FRANCISCO, Calif.-(Business Wire)-January 15, 2009 - Genentech, Inc. (NYSE:DNA) today announced financial results for the full year and fourth quarter of 2008. Key results for the full year 2008 include: U.S. product sales of $9,503 million, an 11 percent increase from $8,540 million in...
87 - Online Resource Illustrates Basic Diagnosis Procedures for Medical School Students
SKANEATELES FALLS, N.Y.-(Business Wire)-January 15, 2009 - Welch Allyn, a leading manufacturer of frontline medical products and solutions, today introduced Diagnosis 101, an online educational resource for medical school students just starting out on their quest to become physicians. The...
88 - DSS, Inc. Invited to Speak at Sales Conference
JUNO BEACH, Fla.-(Business Wire)-January 14, 2009 - DSS, Inc. today announced that Jay Flejter, Vice President of Research and Development and Jeff Clarke, Consulting Engineer, were invited to speak at the Embarcadero Technologies Sales Kickoff meeting in San Francisco on January 12. According to...
89 - LifeLinks™ Unveils ADA/Liability Shield Software/Interpreter Package in Response to Growing Language Discrimination Litigation
NEW YORK-(Business Wire)-January 14, 2009 - Responding to a growing trend in U.S. legislative and judicial interpretations regarding communications related discrimination, LifeLinks™, a leading provider of video remote interpreting and American sign language video relay services, today unveiled an...
90 - NovaBay’s NVC-422 Cleared by FDA for Human Clinical Trials in Ophthalmology
EMERYVILLE, Calif.-(Business Wire)-January 13, 2009 - NovaBay Pharmaceuticals, Inc. (AMEX: NBY, www.novabaypharma.com), announces the clearance of an Investigational New Drug application (IND) submitted by Alcon to the FDA to permit the clinical development of NovaBay’s NVC-422 for infections of...
91 - MacuCLEAR and Mystic Pharmaceuticals Agree To Collaborate on Macular Degeneration Phase I/II Clinical Trial
PLANO, Texas-(Business Wire)-January 13, 2009 - MacuCLEAR, Inc. (“MacuCLEAR”) announced today it has entered into a collaborative business relationship with Mystic Pharmaceuticals Inc. for its upcoming Phase I/II Human Clinical Trials. MacuCLEAR is developing MC 1101, for the treatment and...
92 - CYTTA Introduces Its New Wholly Owned Subsidiary
FOUNTAIN HILLS, Ariz.-(Business Wire)-January 12, 2009 - CYTTA Corporation’s (OTCBB: CYTC) newly acquired wholly owned subsidiary Ophthalmic International (OI) is an innovative manufacturer of medical products. OI has developed and patented a 2-minute, non-invasive, cost effective, alternative...
93 - Kevin Buehler Appointed President and CEO of Alcon; Cary Rayment to Continue as Chairman of the Board
HÜNENBERG, Switzerland-(Business Wire)-January 8, 2009 - Alcon, Inc. (NYSE:ACL) announced today that on April 1, 2009 Kevin Buehler will become president and chief executive officer of Alcon, Inc. Cary Rayment will retire as president and chief executive officer effective March 31, 2009, but will...
94 - Alcon Announces Fourth Quarter 2008 Financial Release and Conference Call Dates
HÜNENBERG, Switzerland-(Business Wire)-January 8, 2009 - Alcon, Inc. (NYSE: ACL) will report on its fourth quarter financial results for the period ended December 31, 2008 after the market close on Wednesday, February 11, 2009. Management of the company will host a conference call to discuss...
95 - High Growth Reported for the World Optical Coatings Market
NEW YORK-(Business Wire)-January 8, 2009 - Reportlinker.com announces that a new market research report related to the Paints - coatings - solvants industry is available in its catalogue. World Optical Coatings Market http://www.reportlinker.com/p098276/World-Optical-Coatings—Market.html...
96 - OptiMedica Taps Stephen P. Hanlon as New Vice President of Research and Development
SANTA CLARA, Calif.-(Business Wire)-January 8, 2009 - Global ophthalmic company OptiMedica Corp. has appointed medical device industry veteran Stephen P. Hanlon as vice president of research and development. In this newly created position, Hanlon will be responsible for driving new technology and...
97 - ORA Names George Bayz President and Chief Executive Officer
PASADENA, Calif.-(Business Wire)-January 7, 2009 - Optical Research Associates (ORA®), a leading provider of optical design software and optical engineering services, has named George Bayz as the company’s new President and Chief Executive Officer, effective immediately. Bayz succeeds former...
98 - Research and Markets: Israel Ophthalmic Devices Investment Opportunities Report with Analysis and Forecasts to 2012
DUBLIN, Ireland-(Business Wire)-January 7, 2009 - Research and Markets has announced the addition of Global Markets Direct's new report "Israel Ophthalmic Devices Investment Opportunities, Analysis and Forecasts to 2012" to their offering. This report is an essential source for in-depth...
99 - Research and Markets: 'Global Ophthalmic Market: Focus On Glaucoma' Focuses on Glaucoma as a Major Ophthalmic Market
DUBLIN, Ireland-(Business Wire)-January 6, 2009 - Research and Markets has announced the addition of the "Global Ophthalmic Market: Focus on Glaucoma" report to their offering. Glaucoma is a type of disease that causes an irreversible blindness, if it is left undetected or untreated. Moreover...
100 - Wells Fargo Purchases Loan and Lease Receivables from GE Healthcare Financial Services – Equipment Finance
DES MOINES, Iowa-(Business Wire)-January 5, 2009 - Wells Fargo & Company (NYSE:WFC) has purchased approximately $730 million in loan and lease receivables from GE Healthcare Financial Services – Equipment Finance, a unit of GE Capital. The acquired receivables from the business formerly...
101 - Inflammatory Factors May be Key to Controlling Diabetic Macular Edema
SAN FRANCISCO-(Business Wire)-January 5, 2009 - With a new study from the Centers for Disease Control and Prevention predicting that diabetic retinopathy will triple from 5.5 million in 2005 to 16 million in 2050, improved treatments are urgently needed for this leading cause of blindness in...
102 - Medtech Insight and Windhover Conferences Announce their Upcoming "Investment In Innovation (In3) West” Conference March 2-4, 2009, Las Vegas, NV
IRVINE, Calif.-(Business Wire)-January 5, 2009 - Medtech Insight, a division of Windhover Conferences and a leading provider of business information for the medical device industry, has announced that more than 30 early- to late-stage companies are confirmed to date to present at their upcoming...
103 - Akorn-Strides, LLC Announces FDA Approvals for Sterile Vancomycin HCl USP, 500 mg/Vial; 1 g/Vial and Sterile Vancomycin HCl USP, 5 g/Vial Pharmacy Bulk Package
LAKE FOREST, Ill.-(Business Wire)-December 31, 2008 - Akorn-Strides, LLC today announced that the U.S. Food and Drug Administration has granted approvals for two Abbreviated New Drug Applications (ANDAs) for Sterile Vancomycin HCl USP, 500 mg/vial, 1 g/vial and Sterile Vancomycin HCl USP, 5 g/vial...
104 - Eye Care and Eyewear Trends for 2009 and Beyond from the Editors of AllAboutVision.com
SAN DIEGO-(Business Wire)-December 30, 2008 - What advances in eye care and eyewear can we expect in 2009 and beyond? The editors of AllAboutVision.com see the following trends and products emerging soon: Researchers are working on liquid-based lenses for use as implanted contact lenses, cataract...
105 - FDA Approves Alcon’s AcrySof® IQ ReSTOR® +3.0 D Intraocular Lens
HUENENBERG, Switzerland-(Business Wire)-December 23, 2008 - Alcon, Inc. (NYSE: ACL), the world’s leader in eye care and cataract surgery announced that the U.S. Food and Drug Administration (FDA) approved its +3.0 diopter add power AcrySof® IQ ReSTOR® IOL. This new lens, which was introduced...
106 - Californian Files Consumer Fraud Class Action against Advanced Medical Optics for Falsely Advertising Contact Lens Solution
SANTA ANA, Calif.-(Business Wire)-December 22, 2008 - Lieff Cabraser Heimann & Bernstein, LLP, and Moscone, Emblidge & Quadra announced that Southern California-based Advanced Medical Optics, Inc. (“AMO”) was named as the defendant in a consumer fraud and false advertising class action...
107 - Californian Files Contact Lens Solution False Advertising Class Action Against Advanced Medical Optics, Announces the Schmidt Firm, LLP
SANTA ANA, Calif.-(Business Wire)-December 22, 2008 - The Schmidt Firm, LLP in Dallas, Texas announced today that Southern California-based Advanced Medical Optics, Inc. (“AMO”) was named as the defendant in a consumer fraud and false advertising class action lawsuit. The case, Maria Ruiz v...
108 - Examine the World Intraocular Lenses Market
NEW YORK-(Business Wire)-December 19, 2008 - Reportlinker.com announces that a new market research report related to the Medical devices industry is available in its catalogue. World Intraocular Lenses Market http://www.reportlinker.com/p098379/World-Intraocular-Lenses—Market.html This...
109 - Phase III Study Showed Rituxan® Decreased the Progression of Joint Damage in Patients with Early Rheumatoid Arthritis (RA)
SOUTH SAN FRANCISCO, Calif. & CAMBRIDGE, Mass.-(Business Wire)-December 19, 2008 - Genentech, Inc. (NYSE:DNA) and Biogen Idec (Nasdaq:BIIB) announced today that a Phase III clinical study of Rituxan® (rituximab) in patients with early rheumatoid arthritis (RA) who have not previously been...
110 - Resolvyx Announces Initiation of Phase I/II Clinical trial of Novel Resolvin Therapeutic RX-10045 in Patients with Dry Eye
BEDFORD, Mass.-(Business Wire)-December 18, 2008 - Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced that it has initiated the first human clinical trial evaluating a resolvin therapeutic, RX-10045, in a Phase I/II clinical trial in patients with...
Search Our News Using Google Search
Can't find what you want? Try using Google:
